{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:00Z","timestamp":1791352200370,"version":"4.3.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among men globally. Its development is driven by a complex interaction of genetic susceptibility, molecular alterations, hormonal signaling, environmental exposures, and lifestyle-related factors. This systematic review synthesizes current evidence on the etiological mechanisms and evolving therapeutic landscape of prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Literature published between January 2010 and December 2025 was searched in PubMed, Scopus, and Web of Science databases. Eligible studies included original research, clinical studies, translational studies, and experimental investigations evaluating prostate cancer etiology, molecular mechanisms, risk factors, biomarkers, or therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review included 29 studies encompassing epidemiological cohorts, clinical studies, genomic analyses, tissue-based investigations, and preclinical experimental studies. Evidence demonstrated that prostate cancer etiology involves multiple interconnected pathways, including androgen receptor signaling, DNA repair alterations, genomic instability, chromatin remodeling, metabolic reprogramming, and inflammatory mechanisms. Genetic variants, including single nucleotide polymorphisms and polygenic risk scores, were associated with disease susceptibility, aggressiveness, treatment response, and toxicity outcomes. Therapeutic advances included optimization of androgen deprivation therapy, novel androgen receptor pathway inhibitors, chemotherapy, radiotherapy personalization, bone-targeted therapies, PSMA-directed radioligand therapy, and emerging immunotherapeutic approaches. Biomarker-driven strategies, including genomic classifiers and molecular signatures, showed potential for improving risk stratification and individualized treatment selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prostate cancer is a biologically heterogeneous disease requiring integrated approaches that combine molecular understanding with clinical decision-making. Recent advances in precision oncology have expanded therapeutic options beyond conventional treatment paradigms, enabling more personalized management strategies. However, further research is required to improve representation of diverse populations, validate biomarkers across different ethnic groups, and optimize the clinical implementation of emerging targeted and immune-based therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261435105.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1941788","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:42Z","timestamp":1791348762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Nakitto Irene","family":"Kisakye","sequence":"first","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Ayebazibwe","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mary Amito","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia D.","family":"Ajambo","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tirwomwe","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"Tiko","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tusingwire","family":"Pliers","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaph","family":"Owamukamaeli","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nduhukire","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngabirano","family":"Chrispuss","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculate","family":"Mandera","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racheal","family":"Owomugisha","sequence":"additional","affiliation":[{"name":"Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swase Dominic","family":"Terkimbi","sequence":"additional","affiliation":[{"name":"Victoria University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"63.","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-023-01121-z","article-title":"Genomic and phenotypic biomarkers for precision medicine guidance in advanced prostate cancer","volume":"24","author":"Davoudi","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13060167","article-title":"Overdiagnosis and overtreatment in prostate cancer","volume":"13","author":"Dushimova","year":"2025","journal-title":"Diseases"},{"key":"B4","article-title":"An in-depth look into the epidemiological and etiological aspects of prostate cancer: a literature review","volume":"15","author":"Al-Ghazawi","year":"2023","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.51722","article-title":"Modern paradigms for prostate cancer detection and management","volume":"217","author":"Williams","year":"2022","journal-title":"Med J Aust"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1006101","article-title":"Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1755","article-title":"Targeting steroid hormone receptors for anti-cancer therapy\u2014A review on small molecules and nanotherapeutic approaches","volume":"14","author":"Mahadik","year":"2022","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.3390\/biom15050625","article-title":"Precision targeting in metastatic prostate cancer: molecular insights to therapeutic frontiers","volume":"15","author":"Kwon","year":"2025","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051359","article-title":"Recent advances in prostate cancer treatment and drug discovery","volume":"19","author":"Nevedomskaya","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/1055-9965.epi-24-1228","article-title":"A polygenic risk score for late bladder toxicity following radiotherapy for non-metastatic prostate cancer","volume":"34","author":"Farazi","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v19i7.9","article-title":"Deltex E3 Ubiquitin Ligase 3L confers radioresistance in prostate cancer via Akt pathway","volume":"19","author":"Xiang","year":"2020","journal-title":"Trop J Pharm Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185447","article-title":"Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness","volume":"12","author":"Robles-Fernandez","year":"2017","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1669","article-title":"CDKN1B deletions are associated with metastasis in African American men with clinically localized, surgically treated prostate cancer","volume":"26","author":"Faisal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110422","article-title":"Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity","volume":"38","author":"Schniewind","year":"2022","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgz129","article-title":"Circulating mRNA signature as a marker for high-risk prostate cancer","volume":"41","author":"De Souza","year":"2020","journal-title":"Carcinogenesis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-19-0407","article-title":"Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk","volume":"29","author":"Creed","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s245861","article-title":"Crosstalk between AR and Wnt signaling promotes castration-resistant prostate cancer growth","volume":"13","author":"Luo","year":"2020","journal-title":"OncoTarg Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00013","article-title":"Development and validation of a genomic tool to predict seminal vesicle invasion in adenocarcinoma of the prostate","volume":"4","author":"Hall","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13489","DOI":"10.1038\/s41598-023-40347-7","article-title":"Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression","volume":"13","author":"Lazniewska","year":"2023","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac073","article-title":"Expression patterns and corepressor function of retinoic acid-induced 2 in prostate cancer","volume":"68","author":"Besler","year":"2022","journal-title":"Clin Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02449-x","article-title":"Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor","volume":"129","author":"Turpin","year":"2023","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24210","article-title":"Phenotypic characterization of two novel cell line models of castration\u2010resistant prostate cancer","volume":"81","author":"Haffner","year":"2021","journal-title":"Prostate"},{"key":"B23","doi-asserted-by":"publisher","first-page":"75979","DOI":"10.18632\/oncotarget.18275","article-title":"Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.7150\/thno.33972","article-title":"HMGB1 promotes prostate cancer development and metastasis by interacting with Brahma-related gene 1 and activating the Akt signaling pathway","volume":"9","author":"Lv","year":"2019","journal-title":"Theranostics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1371\/annotation\/47bdb3be-4110-48de-a29d-e4734e64f6a0","article-title":"Correction: improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGF\u03b21 signaling pathway modulation","volume":"8","author":"Teixeira","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.7150\/jca.22787","article-title":"Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence","volume":"9","author":"Zheng","year":"2018","journal-title":"J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15138","article-title":"Up\u2010regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence","volume":"24","author":"Huang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-23-1047","article-title":"Kinesin facilitates phenotypic targeting of therapeutic resistance in advanced prostate cancer","volume":"22","author":"Archer","year":"2024","journal-title":"Mol Cancer Res"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.12328","article-title":"mi RNA\u2010106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation","volume":"12","author":"Hoey","year":"2018","journal-title":"Mol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054627","article-title":"Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer","volume":"8","author":"Yu","year":"2013","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11081","DOI":"10.1016\/s0167-8140(15)30405-9","article-title":"NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer","volume":"5","author":"Berlin","year":"2014","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.011","article-title":"Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy","volume":"66","author":"Rajan","year":"2014","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4111\/icu.20210305","article-title":"Prediction of clinically significant prostate cancer using polygenic risk models in Asians","volume":"63","author":"Song","year":"2021","journal-title":"Invest Clin Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.12.002","article-title":"Prostate cancer tumor volume and genomic risk","volume":"48","author":"Ramaswamy","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.12.030","article-title":"Prostate cancer risk alleles are associated with prostate cancer volume and prostate size","volume":"191","author":"Reinhardt","year":"2014","journal-title":"J Urol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12935-022-02590-2","article-title":"TNFRSF13B is a potential contributor to prostate cancer","volume":"22","author":"Li","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s136491","article-title":"Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer","author":"Pan","year":"2017","journal-title":"OncoTarg Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016910","article-title":"A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy","volume":"7","author":"Kiwata","year":"2017","journal-title":"BMJ Open"},{"key":"B39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cac2.12137","article-title":"Macrophage inhibitory cytokine\u20101 induced by a high\u2010fat diet promotes prostate cancer progression by stimulating tumor\u2010promoting cytokine production from tumor stromal cells","volume":"41","author":"Huang","year":"2021","journal-title":"Cancer Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000216","article-title":"The role of testosterone in the treatment of castration-resistant prostate cancer","volume":"22","author":"Drazer","year":"2016","journal-title":"Cancer J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0060-y","article-title":"Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer","volume":"21","author":"Miller","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2022.12.031","article-title":"Mapping European Association of Urology guideline practice across Europe: An audit of androgen deprivation therapy use before prostate cancer surgery in 6598 cases in 187 hospitals across 31 European countries","volume":"83","author":"MacLennan","year":"2023","journal-title":"Eur Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.5c00757","article-title":"Evolving Treatments and Resistance Mechanisms in Prostate Cancer Therapeutics","volume":"9","author":"Sai Rishma Reddy","year":"2026","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:44Z","timestamp":1791348764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1941788"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1941788","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1941788"}}